Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes-Reference-Cited by-同舟云学术

Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes

Published:2013-10-03 Issue:14 Volume:122 Page:e33-e43
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Malinge Sébastien¹,Chlon Tim¹,Doré Louis C.¹,Ketterling Rhett P.²,Tallman Martin S.³,Paietta Elisabeth⁴,Gamis Alan S.⁵,Taub Jeffrey W.⁶,Chou Stella T.⁷,Weiss Mitchell J.⁷,Crispino John D.¹,Figueroa Maria E.⁸

Affiliation:

1. Division of Hematology/Oncology, Northwestern University, Chicago, IL;

2. Division of Laboratory Genetics, Mayo Clinic, Rochester, MN;

3. Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY;

4. Department of Oncology, Montefiore Medical Center, Bronx, NY;

5. Division of Hematology/Oncology/Bone Marrow Transplantation, Children’s Mercy Hospitals and Clinics, Kansas City, MO;

6. Division of Hematology/Oncology, Children's Hospital of Michigan, Wayne State University, Detroit, MI;

7. The Children’s Hospital of Philadelphia, Division of Hematology, University of Pennsylvania School of Medicine, Philadelphia, PA; and

8. Department of Pathology, University of Michigan Medical School, Ann Arbor, MI

Abstract

Key Points DNA methylation changes during the development of DS-AMKL occur in sequential waves of opposing losses and gains of methylation. Each wave of DNA methylation abnormalities targets specific gene networks that contribute to distinct biological features of the disease.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/14/e33/1370975/e33.pdf

Reference49 articles.

1. Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children’s Oncology Group Study POG 9421.;O’Brien;Leukemia,2013

2. The management of neoplastic disorders of haematopoiesis in children with Down’s syndrome.;Lange;Br J Haematol,2000

3. Transient leukaemia—a benign form of leukaemia in newborn infants with trisomy 21.;Zipursky;Br J Haematol,2003

4. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome.;Pine;Blood,2007

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inherent genome instability underlies trisomy 21-associated myeloid malignancies;Leukemia;2024-01-20

2. Down syndrome and leukemia: An insight into the disease biology and current treatment options;Blood Reviews;2023-11

3. Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study;Leukemia;2023-02-22

4. Advances in molecular characterization of myeloid proliferations associated with Down syndrome;Frontiers in Genetics;2022-08-10

5. Gene-dosage imbalance due to trisomic HSA21 and genotype–phenotype association in Down syndrome;Genetics and Neurobiology of Down Syndrome;2022